On Mar 14, 2022 Nutcracker Therapeutics closed a Series C round and raised $167,000,000 from ARCH Venture Partners, featuring lead investors ARCH Venture Partners. About […]
Series C – Nutcracker Therapeutics
On Mar 14, 2022 Nutcracker Therapeutics closed a Series C round and raised $167,000,000 from ARCH Venture Partners, featuring lead investors ARCH Venture Partners. About […]
Series B – SmithRx
On Mar 10, 2022 SmithRx closed a Series B round and raised $20,000,000 from Darian Shirazi, Founders Fund, Venrock, featuring lead investors Venrock. About the […]
Series B – SmithRx
On Mar 10, 2022 SmithRx closed a Series B round and raised $20,000,000 from Darian Shirazi, Founders Fund, Venrock, featuring lead investors Venrock. About the […]
Clara Health acquired by M&B Sciences
Mar 9, 2022 M&B Sciences has entered into an agreement to acquire Clara Health . M&B Sciences based at San Diego, California, United States. ” […]
Abcore acquired by Fortis Life Sciences
Mar 2, 2022 Fortis Life Sciences has entered into an agreement to acquire Abcore . Fortis Life Sciences based at Waltham, Massachusetts, United States. ” […]
LivWell Enlightened Health acquired by PharmaCann
Feb 28, 2022 PharmaCann has entered into an agreement to acquire LivWell Enlightened Health . PharmaCann based at Chicago, Illinois, United States. “PharmaCann is a […]
Post-IPO Equity – Jagsonpal Pharmaceuticals
On Feb 21, 2022 Jagsonpal Pharmaceuticals closed a Post-IPO Equity round and raised ₹2,690,000,000 from Convergent Finance, featuring lead investors Convergent Finance. About the company: […]
Post-IPO Equity – Jagsonpal Pharmaceuticals
On Feb 21, 2022 Jagsonpal Pharmaceuticals closed a Post-IPO Equity round and raised ₹2,690,000,000 from Convergent Finance, featuring lead investors Convergent Finance. About the company: […]
Debt Financing – Cheplapharm Arzneimittel
On Feb 11, 2022 Cheplapharm Arzneimittel closed a Debt Financing round and raised €1,480,000,000 from investors, featuring lead investors . About the company: Cheplapharm Arzneimittel […]
